Dextech Medical AB (XSAT:DEX)

Sweden flag Sweden · Delayed Price · Currency is SEK
10.55
+0.30 (2.93%)
At close: Apr 27, 2026
159.85%
Market Cap 195.03M
Revenue (ttm) 3.07M
Net Income (ttm) -5.63M
Shares Out 18.49M
EPS (ttm) -0.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,538
Average Volume 3,382
Open 10.30
Previous Close 10.25
Day's Range 9.94 - 10.80
52-Week Range 4.04 - 14.40
Beta 1.42
RSI 56.19
Earnings Date May 5, 2026

About Dextech Medical AB

Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, or the treatment of acromegaly,... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 1
Stock Exchange Spotlight Stock Market
Ticker Symbol DEX
Full Company Profile

Financial Performance

In fiscal year 2025, Dextech Medical AB's revenue was 3.22 million, a decrease of -40.15% compared to the previous year's 5.39 million. Losses were -4.84 million, 2.96% more than in 2024.

Financial Statements

News

There is no news available yet.